-          Abbvie M14-033 / Serene (Hoge dosis adalimumab):

A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

 

-          Abbvie M14-234 / Achieve (JAK1 inhibitor upadacitinib):

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

 

Abbvie M14-533 / Achieve:

A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC)

 

-          Abbvie P11-282 / Legacy (Long term safety en effectiveness adalimumab):

A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)

 

-          Abivax ABX464-101 (Triggert de secretie van IL22):

A Phase IIa study to evaluate the safety and efficacy of ABX464 50 mg once daily versus Placebo in subjects with Moderate to Severe Active Ulcerative Colitis who have failed or are intolerant to immunomodulators, Anti-TNFα, vedolizumab and/or corticosteroids

 

Abivax ABX464-102:

A follow-up Phase IIa study to evaluate the long-term safety and efficacy profile of ABX464 given at 50 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis.

 

-          Pacific (PK infliximab):

Study of the inter-individual variation of PhArmaCo-kinetics of Infliximab during treatment Induction in patients with crohn’s disease and ulcerative Colitis (PACIFIC)

 

-          Boehringer Ingelheim 1368-0004 (IL36 antagonist):

Exploratory Trial to Assess Mechanism of Action, Clinical  Effect, Safety and Tolerability of 12 Weeks of Treatment with  BI 655130 in Patients with Active Ulcerative Colitis (UC) 

 

-          GA28950 / Hickory (Anti-adhesie etrolizumab):

This is a multicenter, Phase III, double-blind, placebo-controlled study evaluating the safety, efficacy, and tolerability of etrolizumab during induction and maintenance of remission compared with placebo in the treatment of moderately to severely active UC.

 

GA28951 / Cottonwood:

An open-label extension and safety monitoring study of moderate to severe ulcerative colitis patients previously enrolled in etrolizumab phase II/III studies

 

-          Gilead/Galapagos GS-US-419-3898 (JAK1 inhibitor filgotinib):

Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled StudiesEvaluating the Efficacyand Safety of Filgotinibin the Inductionand Maintenanceof  Remissionin Subjects with Moderately to Severely Active Ulcerative Colitis.

 

Gilead/Galapagos GS-US-419-3899:

A Long-TermExtension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis.

 

-          Love UC (Vedolizumab early vs late UC):

An open label interventional phase 4 study to Evaluate Efficacy, Safety and Mucosal Healing of early versus late use of vedolizumab in ulcerative colitis: the LOVE-UC study (LOw countries VEdolizumab in UC study)

 

-          Go-Observe (Anti-TNF golimumab):

European Prospective Observational Cohort Study of Patientreported Continuous Clinical Response to SIMPONI in adults with moderate to severely active Ulcerative Colitis.

 

-          RPC01-3101 / Receptos (activeert S1P1 en S1P5 receptors):

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis

 

RPC01-3102:

A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

 

-          Takeda/UZ Leuven trough levels vedolizumab (Dosisverhoging):

Effect of dose intensification on serum drug concentrations of Entyvio® (vedolizumab) in patients with CD or UC and secondary loss of response

 

-          Takeda Pass (Long term safety vedolizumab. Elke patiënt die op een nieuw biological start. Mag al een biological buiten vedolizumab gehad hebben.):

An international, observational, prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or crohn’s disease: Entyvio long-term safety study.

 

-          RESTORE-UC (stoelgangstransplantaties van superdonoren)

Fecal microbiota transplantation in patients with active ulcerative colitis:  Restoration of the microbiome through superdonor selection

 

-          Earnest (Vedolizumab pouchitis):

        A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST)

 

 

-          ACH UCP-301 (Alicaforsen enema pouchitis):

       A Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects with Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis

 

 

Copyright CIMW   |   info@ibd-leuven.com   | |     |   
Go to top